<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

TMI 005 - Apratastat

產(chǎn)品貨號

Axon 1507 CAS [287405-51-0] MF C17H22N2O6S2MW 414.50 Purity: 99% Optical purity: >98% ee Soluble in DMSO Description Novel, oral TACE/MMP inhibitor for rheumatoid arthritis; Apratastat (TMI-005) blocks secretion of soluble TNF-α and down regulates multiple MMPs, which have been implicated in cartilage destruction and bone erosions of RA References Certificates Categories Extra info MM Thabet and TWJ Huizinga. Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Investig. Drugs. 2006,?7(11), 1014-1019. ? ML Moss et al. Drug Insight: Tumor Necrosis Factor Converting Enzyme as a Pharmaceutical Target for Rheumatoid Arthritis. Nat. Clin. Pract. Rheumatol. 2008, 4(6), 300.? ? C Shu et al. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. J. Clin. Pharmacol. 2011, 51(4), 472-481.? Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Signaling & Oncology Immunology Miscellaneous Pain & Inflammation TACE NF-κB EC 3.4.24.86 TACE/MMP inhibitor Chemical name (S)-4-[4-(4-Hydroxy-but-2-ynyloxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide Parent CAS No. [287405-51-0] Order Size Unit Price Stock 5 mg €125.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

TMI 005 - Apratastat

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1507

CAS [287405-51-0]

MF C17H22N2O6S2
MW 414.50

Purity: 99%
Optical purity: >98% ee
Soluble in DMSO

TMI 005

Description

Novel, oral TACE/MMP inhibitor for rheumatoid arthritis; Apratastat (TMI-005) blocks secretion of soluble TNF-α and down regulates multiple MMPs, which have been implicated in cartilage destruction and bone erosions of RA

MM Thabet and TWJ Huizinga. Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Investig. Drugs. 2006,?7(11), 1014-1019.

ML Moss et al. Drug Insight: Tumor Necrosis Factor Converting Enzyme as a Pharmaceutical Target for Rheumatoid Arthritis. Nat. Clin. Pract. Rheumatol. 2008, 4(6), 300.?

C Shu et al. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. J. Clin. Pharmacol. 2011, 51(4), 472-481.?

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Signaling & Oncology Immunology Miscellaneous Pain & Inflammation TACE NF-κB EC 3.4.24.86

TACE/MMP inhibitor

Chemical name

(S)-4-[4-(4-Hydroxy-but-2-ynyloxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide

Parent CAS No.

[287405-51-0]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>